Divide And Conquer: Boston Scientific Plots Strategy To Segment DES Market
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to protect its projected share of the drug-eluting stent market by making Taxus the first DES to earn a series of sub-population indications
You may also be interested in...
Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System
Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs
Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System
Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette